利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.034 秒)

    Iodothyronine compositions
    12.
    发明申请
    Iodothyronine compositions 有权
    碘甲腺氨酸组成

    公开(公告)号：US20040087483A1

    公开(公告)日：2004-05-06

    申请号：US10136433

    申请日：2002-05-02

    申请人： New River Pharmaceuticals, Inc.

    发明人： Thomas Piccariello ,  Lawrence Peter Olon ,  Alex Saunders Goldstein ,  James Scott Moncrief ,  Nancy Johnston Boerth

    IPC分类号： A61K038/00

    CPC分类号： A61K47/645 ,  A61K47/62

    摘要： The present invention relates to compositions comprising an active agent. More specifically, the invention relates to active agent compositions that include a peptide carrier and an active agent covalently attached to at least one of the N-terminus, the C-terminus, a side chain of the peptide carrier, and/or interspersed within the peptide chain; methods for protecting and administering active agents; and methods for treating thyroid disorders.

    摘要翻译： 本发明涉及包含活性剂的组合物。 更具体地说，本发明涉及活性剂组合物，其包括肽载体和共价连接至N-末端，C-末端，肽载体的侧链和/或分散在其中的活性剂 肽链; 用于保护和施用活性剂的方法; 和治疗甲状腺疾病的方法。

    ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS
    13.
    发明申请
    ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS 有权
    抗生素赖氨酸AMPHETAMINE化合物

    公开(公告)号：US20080086016A1

    公开(公告)日：2008-04-10

    申请号：US11745019

    申请日：2007-05-07

    申请人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard Paul ,  Christopher Verbicky

    发明人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard Paul ,  Christopher Verbicky

    IPC分类号： C07C233/00

    CPC分类号： A61K31/165 ,  A61K47/542 ,  C07C237/06 ,  Y02A50/415 ,  Y10S436/901 ,  Y10T436/173845

    摘要： The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

    摘要翻译： 本发明描述了使用其包含与苯丙胺共价连接的赖氨酸的化合物，组合物和方法。 这些化合物和组合物可用于减少或预防滥用和过量安非他明。 这些化合物和组合物特别用于提供某些障碍（例如注意力缺陷多动障碍（ADHD），ADD，发作性睡病和肥胖）的耐药性替代治疗。 苯丙胺的口服生物利用度维持在治疗有用的剂量。 在较高剂量下，生物利用度显着降低，从而提供减少口服滥用责任的方法。 此外，本发明的化合物和组合物通过肠胃外途径（例如静脉内或鼻内给药）降低苯丙胺的生物利用度，进一步限制其滥用责任。

    Abuse-resistant hydrocodone compounds
    14.
    发明申请
    Abuse-resistant hydrocodone compounds 有权
    滥用抗氢可可酮化合物

    公开(公告)号：US20050266070A1

    公开(公告)日：2005-12-01

    申请号：US10953110

    申请日：2004-09-30

    申请人： Travis Mickle ,  Suma Krishnan ,  James Moncrief ,  Christopher Lauderback ,  Christal Miller

    发明人： Travis Mickle ,  Suma Krishnan ,  James Moncrief ,  Christopher Lauderback ,  Christal Miller

    IPC分类号： A61K9/48 ,  A61K38/08 ,  A61K47/48

    CPC分类号： A61K38/08 ,  A61K47/64

    摘要： The present invention decreases the potential for abuse of opioids, particularly hydrocodone, by covalent modification. The invention provides methods of delivering hydrocodone as conjugates that release the hydrocodone following oral administration while being resistant to abuse by circuitous routes such as intravenous (“shooting”) injection and intranasal administration (“snorting”). Further, hydrocodone compositions of the invention are resistant to oral abuse as well, since release of the hydrocodone at suprapharmacological doses reaches saturation.

    摘要翻译： 本发明通过共价修饰降低了阿片样物质，特别是氢可酮的滥用的可能性。 本发明提供了递送氢可酮作为缀合物的方法，其在口服给药之后释放氢可酮，同时抵抗诸如静脉内（“射击”）注射和鼻内给药（“嗅觉”）等迂回途径的滥用。 此外，本发明的氢可酮组合物也耐口服滥用，因为以超药物剂量的氢可酮的释放达到饱和。

    Prodrugs of Ribavirin with Improved Hepatic Delivery
    15.
    发明申请
    Prodrugs of Ribavirin with Improved Hepatic Delivery 审中-公开
    利巴韦林与改善肝脏输送的药物

    公开(公告)号：US20080260691A1

    公开(公告)日：2008-10-23

    申请号：US11718311

    申请日：2005-11-02

    申请人： Travis Mickle ,  Sven Guenther

    发明人： Travis Mickle ,  Sven Guenther

    IPC分类号： A61K38/16 ,  C07K2/00 ,  A61P31/12 ,  A61K38/21 ,  C07K9/00

    CPC分类号： C07K9/003

    摘要： The present invention relates ribavirin delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to ribavarin and methods for administering conjugated ribavirin compositions.

    摘要翻译： 本发明涉及利巴韦林递送系统，更具体地涉及包含共价连接到利巴韦林的氨基酸，单个氨基酸或肽的组合物和用于施用缀合的利巴韦林组合物的方法。

    Abuse-resistant hydrocodone compounds
    17.
    发明授权
    Abuse-resistant hydrocodone compounds 有权
    滥用抗氢可可酮化合物

    公开(公告)号：US07338939B2

    公开(公告)日：2008-03-04

    申请号：US10953110

    申请日：2004-09-30

    申请人： Travis Mickle ,  Suma Krishnan ,  James Scott Moncrief ,  Christopher Lauderback ,  Christal Miller

    发明人： Travis Mickle ,  Suma Krishnan ,  James Scott Moncrief ,  Christopher Lauderback ,  Christal Miller

    IPC分类号： A61K38/00

    CPC分类号： A61K38/08 ,  A61K47/64

    摘要： The present invention decreases the potential for abuse of opioids, particularly hydrocodone, by covalent modification. The invention provides methods of delivering hydrocodone as conjugates that release the hydrocodone following oral administration while being resistant to abuse by circuitous routes such as intravenous (“shooting”) injection and intranasal administration (“snorting”). Further, hydrocodone compositions of the invention are resistant to oral abuse as well, since release of the hydrocodone at suprapharmacological doses reaches saturation.

    摘要翻译： 本发明通过共价修饰降低了阿片样物质，特别是氢可酮的滥用的可能性。 本发明提供了递送氢可酮作为缀合物的方法，其在口服给药之后释放氢可酮，同时抵抗诸如静脉内（“射击”）注射和鼻内给药（“嗅觉”）等迂回途径的滥用。 此外，本发明的氢可酮组合物也耐口服滥用，因为以超药物剂量的氢可酮的释放达到饱和。

    Abuse resistant lysine amphetamine compounds
    18.
    发明授权
    Abuse resistant lysine amphetamine compounds 有权
    滥用抗性赖氨酸苯丙胺化合物

    公开(公告)号：US07223735B2

    公开(公告)日：2007-05-29

    申请号：US10857619

    申请日：2004-06-01

    申请人： Travis Mickle ,  Suma Krishnan ,  James Scott Moncrief ,  Christopher Lauderback ,  Barney Bishop ,  Rob Oberlender ,  Thomas Piccariello

    发明人： Travis Mickle ,  Suma Krishnan ,  James Scott Moncrief ,  Christopher Lauderback ,  Barney Bishop ,  Rob Oberlender ,  Thomas Piccariello

    IPC分类号： A61K38/00

    CPC分类号： A61K31/165 ,  A61K47/542 ,  C07C237/06 ,  Y02A50/415 ,  Y10S436/901 ,  Y10T436/173845

    摘要： The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

    摘要翻译： 本发明描述了使用其包含与苯丙胺共价连接的赖氨酸的化合物，组合物和方法。 这些化合物和组合物可用于减少或预防滥用和过量安非他明。 这些化合物和组合物特别用于提供某些障碍（例如注意力缺陷多动障碍（ADHD），ADD，发作性睡病和肥胖）的耐药性替代治疗。 苯丙胺的口服生物利用度维持在治疗有用的剂量。 在较高剂量下，生物利用度显着降低，从而提供减少口服滥用责任的方法。 此外，本发明的化合物和组合物通过肠胃外途径（例如静脉内或鼻内给药）降低苯丙胺的生物利用度，进一步限制其滥用责任。

    Abuse-resistant amphetamine prodrugs
    19.
    发明申请
    Abuse-resistant amphetamine prodrugs 有权
    滥用安非他明前药

    公开(公告)号：US20070042955A1

    公开(公告)日：2007-02-22

    申请号：US11400304

    申请日：2006-04-10

    申请人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Moncrief ,  Rob Oberlender ,  Thomas Piccariello

    发明人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Moncrief ,  Rob Oberlender ,  Thomas Piccariello

    IPC分类号： A61K38/16 ,  A61K38/10 ,  A61K38/08 ,  A61K38/06 ,  A61K38/05 ,  A61K38/04 ,  A61K31/198

    CPC分类号： A61K31/165 ,  A61K47/542 ,  C07C237/06 ,  Y10S436/901 ,  Y10T436/173845

    摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

    摘要翻译： 本发明描述了使用包含与苯丙胺共价连接的化学部分的化合物，组合物和方法。 这些化合物和组合物可用于减少或预防滥用和过量安非他明。 这些化合物和组合物特别用于提供某些障碍（例如注意力缺陷多动障碍（ADHD），ADD，发作性睡病和肥胖）的耐药性替代治疗。 苯丙胺的口服生物利用度维持在治疗有用的剂量。 在较高剂量下，生物利用度显着降低，从而提供减少口服滥用责任的方法。 此外，本发明的化合物和组合物通过肠胃外途径（例如静脉内或鼻内给药）降低苯丙胺的生物利用度，进一步限制其滥用责任。